Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection

Autores
Flor, Noelia; García, María Inés; Molineri, Ana Ines; Botasso, Oscar; Diez, Cristina; Veaute, Carolina
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.
EEA Rafaela
Fil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: García, María Ines. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: Molineri, Ana Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina
Fil: Molineri, Ana Ines. Consejo Nacional de Ciencia y Tecnología (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina
Fil: Molineri, Ana Ines. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina
Fil: Botasso, Oscar. Universidad Nacional de Rosario; Argentina
Fil: Botasso, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Inmunología clínica y Experimental de Rosario (IDICER); Argentina
Fil: Diez, Cristina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina
Fil: Veaute; Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: Veaute, Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina
Fuente
Vaccine 41 (48) : 7206-7211 (2023)
Materia
Vacuna
Inmunidad
COVID-19
Coronavirus del síndrome respiratorio agudo grave 2
Vaccines
Immunity
Severe acute respiratory syndrome coronavirus 2
Serovigilancia
SARS-CoV2
Serosurveillance
Nivel de accesibilidad
acceso restringido
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/16258
Acceder
id INTADig_0d8c87cead18eb95752bb906dcae0384
oai_identifier_str oai:localhost:20.500.12123/16258
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infectionFlor, NoeliaGarcía, María InésMolineri, Ana InesBotasso, OscarDiez, CristinaVeaute, CarolinaVacunaInmunidadCOVID-19Coronavirus del síndrome respiratorio agudo grave 2VaccinesImmunitySevere acute respiratory syndrome coronavirus 2SerovigilanciaSARS-CoV2SerosurveillanceThe COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.EEA RafaelaFil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; ArgentinaFil: García, María Ines. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; ArgentinaFil: Molineri, Ana Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; ArgentinaFil: Molineri, Ana Ines. Consejo Nacional de Ciencia y Tecnología (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); ArgentinaFil: Molineri, Ana Ines. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); ArgentinaFil: Botasso, Oscar. Universidad Nacional de Rosario; ArgentinaFil: Botasso, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Inmunología clínica y Experimental de Rosario (IDICER); ArgentinaFil: Diez, Cristina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; ArgentinaFil: Veaute; Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; ArgentinaFil: Veaute, Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; ArgentinaElsevier2023-12-15T17:58:19Z2023-12-15T17:58:19Z2023-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/16258https://www.sciencedirect.com/science/article/abs/pii/S0264410X230122151873-25180264-410Xhttps://doi.org/10.1016/j.vaccine.2023.10.038Vaccine 41 (48) : 7206-7211 (2023)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/restrictedAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-09-29T13:46:16Zoai:localhost:20.500.12123/16258instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-09-29 13:46:17.112INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
spellingShingle Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
Flor, Noelia
Vacuna
Inmunidad
COVID-19
Coronavirus del síndrome respiratorio agudo grave 2
Vaccines
Immunity
Severe acute respiratory syndrome coronavirus 2
Serovigilancia
SARS-CoV2
Serosurveillance
title_short Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_full Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_fullStr Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_full_unstemmed Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
title_sort Antibodies to SARS-CoV2 induced by vaccination and infection correlate with protection against the infection
dc.creator.none.fl_str_mv Flor, Noelia
García, María Inés
Molineri, Ana Ines
Botasso, Oscar
Diez, Cristina
Veaute, Carolina
author Flor, Noelia
author_facet Flor, Noelia
García, María Inés
Molineri, Ana Ines
Botasso, Oscar
Diez, Cristina
Veaute, Carolina
author_role author
author2 García, María Inés
Molineri, Ana Ines
Botasso, Oscar
Diez, Cristina
Veaute, Carolina
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Vacuna
Inmunidad
COVID-19
Coronavirus del síndrome respiratorio agudo grave 2
Vaccines
Immunity
Severe acute respiratory syndrome coronavirus 2
Serovigilancia
SARS-CoV2
Serosurveillance
topic Vacuna
Inmunidad
COVID-19
Coronavirus del síndrome respiratorio agudo grave 2
Vaccines
Immunity
Severe acute respiratory syndrome coronavirus 2
Serovigilancia
SARS-CoV2
Serosurveillance
dc.description.none.fl_txt_mv The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.
EEA Rafaela
Fil: Flor, Noelia. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: García, María Ines. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: Molineri, Ana Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Estación Experimental Agropecuaria Rafaela; Argentina
Fil: Molineri, Ana Ines. Consejo Nacional de Ciencia y Tecnología (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina
Fil: Molineri, Ana Ines. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Investigación de la Cadena Láctea (IDICAL); Argentina
Fil: Botasso, Oscar. Universidad Nacional de Rosario; Argentina
Fil: Botasso, Oscar. Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET). Instituto de Inmunología clínica y Experimental de Rosario (IDICER); Argentina
Fil: Diez, Cristina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina
Fil: Veaute; Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Inmunología Experimental; Argentina
Fil: Veaute, Carolina. Universidad Nacional del Litoral. Facultad de Bioquímica y Ciencias Biológicas. Laboratorio de Biología Molecular e Inmunología Aplicadas; Argentina
description The COVID-19 pandemic remained worldwide for almost three years, but little is known about the dynamics of humoral immune response to the third dose over time and its protection from infection. Our aim was to assess the humoral immune response after the third dose of the different vaccines administered to SARS-CoV-2 naive and previously infected individuals, and its correlation with protection in an academic community. For each person studied (185), three blood samples were taken between December 2021 and July 2022, one month apart. Anti-S antibodies were quantified by ELISA, while anti-N antibody levels were determined by ECLIA. Most of the participants had received two doses of viral vector-based, mRNA-based and virus-inactivated vaccines. Although anti-N antibody levels revealed that 80% of the individuals had been exposed to the virus before or during the study, only 42% reported having been diagnosed. When anti-S IgG levels were measured 3–5 months after the second dose of any vaccine, they were higher in those previously infected individuals. The same results were observed for anti-N IgG levels in those who received 2 doses of the virus-inactivated vaccine. When analyzing the dynamics of anti-S antibodies we observed that, although positive IgG antibody levels were detected 5–6 months after the second dose administration, those observed 30–60 days after the third dose were significantly higher and remained so for at least 8 months. Higher levels of anti-S IgG antibodies at the first sampling were associated with a lower incidence of subse quent infection. The same association was seen in people who received the booster compared with those who received two doses. This study provides further evidence that anti-S IgG antibodies remained at high levels over time, and both anti-S levels and the third dose of anti-SARS-CoV-2 vaccine correlate with protection against the infection. It also shows that infection acts as a booster of immunization, increasing levels of both anti-N and anti-S IgG.
publishDate 2023
dc.date.none.fl_str_mv 2023-12-15T17:58:19Z
2023-12-15T17:58:19Z
2023-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/16258
https://www.sciencedirect.com/science/article/abs/pii/S0264410X23012215
1873-2518
0264-410X
https://doi.org/10.1016/j.vaccine.2023.10.038
url http://hdl.handle.net/20.500.12123/16258
https://www.sciencedirect.com/science/article/abs/pii/S0264410X23012215
https://doi.org/10.1016/j.vaccine.2023.10.038
identifier_str_mv 1873-2518
0264-410X
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/restrictedAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv restrictedAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Vaccine 41 (48) : 7206-7211 (2023)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1844619182988066816
score 12.558318

Publicaciones similares